Comprehensive Clinical Evaluation of Multi-System Metabolic Homeostasis and Longitudinal Physiological Fitness

The laboratory data provided for Phani R. Pilli, a 55-year-old male, dated December 18, 2025, represents a critical temporal snapshot in the management of complex metabolic and endocrine disorders. This evaluation, conducted through the sophisticated lens of the Physiological Fitness Landscape (PFL) and systems biology, seeks to integrate disparate biomarkers into a unified narrative of health and disease progression. The patient is currently under the specialized care of Dr. Brian Fertig, whose clinical philosophy emphasizes the marriage of biophysics and clinical medicine to identify the root causes of metabolic dysregulation. The longitudinal data, spanning from early 2023 to the present, reveals a patient in a state of dynamic transition, characterized by significant improvements in inflammatory and musculoskeletal markers, alongside persistent challenges in glycemic control and a paradoxical lipid profile.

Longitudinal Glycemic Regulation and Pancreatic Beta-Cell Resilience

The primary metabolic challenge for the patient is the management of Type 2 Diabetes Mellitus (T2DM). The current assessment reveals a fasting serum glucose of 141~mg/dL and a Hemoglobin A1c (HbA1c) of 7.1%. While both values remain above the optimal physiological targets, they must be interpreted within the context of a highly fluctuating historical trajectory.

Hemoglobin A1c and Glucose Trajectory Analysis

The HbA1c measurement serves as a weighted average of glycemia over the preceding 90 to 120 days, reflecting the non-enzymatic glycation of hemoglobin within the red blood cell. The patient's HbA1c has shown a promising downward trend from a peak of 8.2% in March 2025 to the current 7.1%.

Date	HbA1c (%)	Glycemic Status	Estimated Average Glucose (mg/dL)
12/13/2024	7.0	Above Goal	154
03/12/2025	8.2	Diabetic (Uncontrolled)	189
06/06/2025	8.1	Diabetic (Uncontrolled)	186
09/12/2025	7.4	Above Goal	166
12/18/2025	7.1	Above Goal	157

The current HbA1c of 7.1% remains above the American Diabetes Association's general target of <7.0% but indicates significant therapeutic progress. In the context of the PFL, the reduction from 8.2% to 7.1% represents a movement away from a high-entropy state where chronic hyperglycemia accelerates tissue damage via the formation of advanced glycation end-products (AGEs). However, the current fasting glucose of 141~mg/dL, labeled as "High" (Ref: 70–99), suggests that the patient continues to experience significant dawn phenomenon or persistent hepatic gluconeogenesis.

A critical nuance in interpreting the patient's HbA1c is the concomitant finding of a low Mean Corpuscular Hemoglobin Concentration (MCHC) of 31.3~g/dL. Emerging research in metabolic biophysics suggests that alterations in red blood cell indices can skew HbA1c results. Low MCHC, often indicative of iron deficiency or anemia of chronic disease, can lead to a false elevation of HbA1c independent of actual blood sugar levels. This occurs because iron-deficient red cells may have an altered circulating lifespan, allowing more time for the glycation of available hemoglobin. Consequently, the patient's true average glucose might be slightly lower than the 7.1% reflects, though the value still confirms a diabetic state requiring ongoing intervention.

Pancreatic Beta-Cell Function: The C-Peptide Paradox

The assessment of C-peptide provides an essential window into the patient's endogenous insulin production capacity. Unlike insulin, which has a short half-life and is subject to significant first-pass hepatic metabolism, C-peptide is cleared more slowly and linearly, primarily by the kidneys, making it a superior marker for beta-cell reserve.

Lab Report Analysis and Health Summary

overcome peripheral insulin resistance.
The reduction to 1.5~ng/mL could signify one of two divergent paths in the patient's Physiological Fitness Landscape:

1. **Metabolic Restoration**: The decline may reflect a "resting" of the pancreas as insulin sensitivity improves, perhaps through weight loss, dietary changes, or the use of insulin-sensitizing medications like Metformin or GLP-1 receptor agonists.
2. **Beta-Cell Exhaustion**: Conversely, it could represent the early stages of beta-cell failure, where the pancreas is no longer able to sustain high-volume insulin output.

Given that the patient's HbA1c and glucose levels have also decreased during this period, the "metabolic restoration" hypothesis is more plausible. However, the patient must be monitored closely; if C-peptide falls below 0.5-0.6~ng/mL in the face of rising glucose, it would indicate a transition toward insulin dependency.

Paradoxical Dyslipidemia and the Risk of Vascular Complications

The lipid panel results from December 18, 2025, present a configuration that is both clinically protective and metabolically concerning. The panel is dominated by extremely low LDL cholesterol and total cholesterol, but persistent hypertriglyceridemia and low HDL.

The LDL Cholesterol Threshold: Benefits and Theoretical Risks

The patient's LDL cholesterol, calculated via the NIH equation, is 20~mg/dL, a significant reduction from the previous level of 57~mg/dL. Total cholesterol has also reached a low of 85~mg/dL.

Lipid Biomarker	Current (mg/dL)	Previous (mg/dL)	Reference Interval
Total Cholesterol	85 (Low)	135	100-199
LDL Cholesterol	20 (Low)	57	0-99
Triglycerides	209 (High)	192	0-149
HDL Cholesterol	32 (Low)	46	>39
VLDL Cholesterol	33	32	5-40

In contemporary cardiology, the mandate for high-risk diabetic patients is "lower is better" regarding LDL cholesterol. An LDL of 20~mg/dL is generally the result of intensive pharmacotherapy, such as high-intensity statins (Atorvastatin 40/80mg or Rosuvastatin 20/40mg) often in combination with Ezetimibe. Such low levels are associated with the stabilization and even regression of atherosclerotic plaques.
However, the patient must be aware of the "U-shaped" mortality curve identified in some large-scale observational studies of diabetic patients. Research from South Korea suggests that among diabetic patients *not* taking statins, a decrease in LDL to extremely low levels (below 40-50~mg/dL) can be a surrogate marker for underlying health issues such as malnutrition, liver disease, or chronic inflammation. In Phani Pilli's case, since he is under the care of a specialist (Dr. Fertig) and his inflammatory markers have normalized, this low LDL is almost certainly a successful therapeutic outcome rather than a sign of systemic decline.

Hypertriglyceridemia and the Atherogenic Particle Burden

Despite the success in lowering LDL, the Triglyceride level has risen to 209~mg/dL, and HDL has dropped to 32~mg/dL. This pattern is known as the "atherogenic lipid triad" of diabetes. High triglycerides facilitate the formation of small, dense LDL (sdLDL) particles. These particles are particularly dangerous because they easily penetrate the arterial wall and are highly prone to oxidation, which triggers the inflammatory cascade leading to plaque formation.
Even with a total LDL mass of only 20~mg/dL, the *number* of particles (LDL-P) could be high if they are predominantly small and dense. Furthermore, the non-fasting status of the latest test influences the triglyceride result. Postprandial triglycerides can rise significantly, although current guidelines suggest that non-fasting triglycerides >200~mg/dL remain a robust indicator of increased cardiovascular risk.
The patient's HDL of 32~mg/dL is below the "Average Risk" threshold for men (>39~mg/dL). HDL is vital for reverse cholesterol transport—the process of carrying excess cholesterol from the periphery back to the liver for excretion. A low HDL level in a diabetic patient is often a consequence of high triglyceride levels, as the Cholesterol Ester Transfer Protein (CETP) swaps triglycerides from VLDL into HDL particles, which are then rapidly cleared by the liver.

Renal Integrity and the Dynamics of Nitrogenous Waste

The Comprehensive Metabolic Panel (CMP) reveals a sophisticated interplay between renal filtration and whole-body hydration. The patient's Creatinine is 0.76~mg/dL, yielding an Estimated Glomerular Filtration

Lab Report Analysis and Health Summary

The BUN/Creatinine Ratio has increased to 21, exceeding the reference range of 9-20. This elevation, occurring in the presence of a normal creatinine level, is a classic marker of prerenal factors rather than intrinsic kidney damage.

Kidney Marker	Current Result	Units	Reference Interval
BUN	16	mg/dL	6-24
Creatinine	0.76	mg/dL	0.76-1.27
BUN/Cr Ratio	21 (High)	ratio	9-20
eGFR	106	mL/min/1.73m^2	>59

The most common driver of a ratio >20 is mild dehydration. In a state of reduced fluid intake or increased loss, the kidneys respond by maximizing water reabsorption. This process also causes the reabsorption of urea (BUN) back into the peritubular capillaries, whereas creatinine is generally not reabsorbed and continues to be excreted. Other contributing factors for this patient could include a high-protein diet, which is frequently recommended for diabetic patients to improve glycemic control, as protein metabolism generates more nitrogenous waste.

Importantly, the patient's Urine Albumin/Creatinine Ratio (uACR) is 12~mg/g (Ref: 0-29), confirming the absence of microalbuminuria. This indicates that the delicate filtration barrier of the glomerulus remains intact, and the patient has not developed diabetic nephropathy despite his historical HbA1c elevations.

Hematological Signatures and the Oxygen Carrying Capacity

The Complete Blood Count (CBC) is a fundamental assessment of the body's ability to transport oxygen and respond to immunological challenges. For this patient, the most significant finding is the subtle drop in MCHC to 31.3~g/dL.

Hypochromia and Red Cell Indices

MCHC (Mean Corpuscular Hemoglobin Concentration) reflects the concentration of hemoglobin within each red blood cell. A value of 31.3 is below the 31.5–35.7 range. This condition, hypochromia, suggests that the patient's red blood cells are "paler" than normal because they are not fully saturated with hemoglobin.

Hematology Index	Result	Units	Reference Range
RBC Count	5.11	x10^6/uL	4.14-5.80
Hemoglobin	14.2	g/dL	13.0-17.7
Hematocrit	45.3	%	37.5-51.0
MCV	89	fL	79-97
MCHC	31.3 (Low)	g/dL	31.5-35.7

Because the MCV (Mean Corpuscular Volume) is normal at 89~fL, the patient exhibits a "normocytic hypochromic" pattern. While his hemoglobin level (14.2~g/dL) is not anemic, the low MCHC is often an early harbinger of iron deficiency or anemia of chronic disease (ACD).

In patients with diabetes, ACD is driven by chronic low-grade inflammation. This inflammation triggers the production of hepcidin, which inhibits the transport of iron into the plasma, effectively starving the red blood cell precursors of the iron needed to produce hemoglobin. Given the patient's previous high hs-CRP (6.52~mg/L), this inflammatory sequestration of iron is a likely candidate for the low MCHC. Additionally, nutritional factors must be considered; long-term use of certain diabetic medications can interfere with the absorption of Vitamin B12 and Folate, which can eventually impact red cell maturation and hemoglobin density.

Systemic Inflammation and Musculoskeletal Resilience

One of the most encouraging aspects of the current lab report is the resolution of previously high inflammatory and muscle-stress markers. This shift reflects a significant increase in the patient's "physiological fitness" and systemic stability.

The hs-CRP Recovery: Moving Toward Cardiovascular Safety

The high-sensitivity C-Reactive Protein (hs-CRP) is a precise measure of systemic inflammation produced by the liver in response to cytokines like IL-6. The patient's current level is 0.42~mg/L, a massive improvement from 6.52~mg/L recorded in September 2025.

Inflammatory Marker	Current Result	Previous (09/12/2025)	Risk Category
hs-CRP	0.42~mg/L	6.52~mg/L	Current: Low Risk / Prev: High Risk

Lab Report Analysis and Health Summary

have been anything from a hidden infection to the inflammation associated with high blood sugar.

Creatine Kinase and Muscle Homeostasis

Similarly, the Total Creatine Kinase (CK) has dropped to 129~U/L from a previous high of 583~U/L. CK is an enzyme found in muscle tissue; elevations typically indicate muscle strain, injury, or the use of certain medications like statins.
A value of 583 is more than double the normal limit (331~U/L) and is consistent with moderate muscle stress. The return to 129 indicates that the patient's muscle tissue is no longer undergoing significant breakdown. If the patient is on statins, this normalization is particularly reassuring, as it suggests that the therapy is being tolerated well without causing the adverse effect of myopathy.

Endocrine Health: Androgens, Thyroid, and Vitamin D

The hormonal markers in this report reflect a patient with healthy endocrine resilience, providing a robust foundation for his metabolic management.

Testosterone and SHBG: The Androgenic Reservoir

At age 55, maintaining healthy testosterone levels is essential for body composition and insulin sensitivity. The patient's Total Testosterone is 426~ng/dL, which is well above the 300~ng/dL threshold for clinical deficiency.

Hormone	Result	Units	Reference Interval
Total Testosterone	426	ng/dL	Adult Male: 264-916
SHBG	32.5	nmol/L	>49y: 19.3-76.4
TSH	1.610	uIU/mL	0.450-4.500

Sex Hormone Binding Globulin (SHBG) is 32.5~nmol/L. This is an optimal result, as SHBG levels often decline in obesity and insulin resistance. A mid-range SHBG combined with a Total Testosterone of 426 suggests that the patient likely has a healthy level of "Free Testosterone" (the biologically active form), which supports lean muscle mass and metabolic vigor.
Thyroid function, as measured by TSH (1.610~uIU/mL) and Free T4 (1.46~ng/dL), is also perfectly within the euthyroid range. Healthy thyroid function is a prerequisite for a healthy basal metabolic rate and lipid clearance.

Vitamin D Optimization

The patient's Vitamin D (25-Hydroxy) level is 60.6~ng/mL, having risen from 49.5~ng/mL. Clinical sufficiency is defined as >30~ng/mL, but many experts in functional metabolism, including Dr. Fertig, target levels in the 50-80~ng/mL range for optimal immune and glycemic benefit. Vitamin D acts as a transcriptional regulator for genes involved in the insulin signaling pathway; thus, this level represents a strong "order parameter" in the patient's PFL.

Integrative Analysis: The Physiological Fitness Landscape Summary

The health of Phani R. Pilli, when analyzed as a complex dynamical system, shows a clear transition from a state of high entropy (high HbA1c, high inflammation, high muscle stress) toward a state of relative metabolic order.

Summary of Systemic Anomalies

Category	Finding	Health Implication
Glycemia	HbA1c 7.1%, Gluc 141	Persistent but improving T2DM; above target goal of 7.0%.
Beta-Cell	C-Peptide 1.5 (down from 3.5)	Potential normalization of insulin output or early pancreatic rest.
Lipids	LDL 20, Total Chol 85	Extremely low cholesterol; highly protective for heart, but check for side effects.

Lab Report Analysis and Health Summary

Renal	BUN/Cr Ratio 21	Mild dehydration or high protein intake; filtration is intact.
Hematology	MCHC 31.3 (Low)	Hypochromia; early signal of iron deficiency or inflammation.
Inflammation	hs-CRP 0.42 (down from 6.52)	Major success; systemic inflammation has been suppressed.

The reduction in hs-CRP and CK suggests that the body's "stress response" has stabilized. The "allostatic load"—the physiological cost of maintaining homeostasis—has decreased significantly between September and December 2025. The current challenge is the "residual risk" posed by the rise in triglycerides and the slight drop in HDL, which can occur as a metabolic "overshoot" during aggressive LDL lowering or as a result of dietary carbohydrate excess.

Clinical Outlook and Pathophysiological Direction

The patient is moving toward a state of improved resilience. To further optimize the Physiological Fitness Landscape, the following narrative insights are offered:

1. **Addressing Hypochromia**: The low MCHC of 31.3, while subtle, should be investigated with a full iron panel (Ferritin, TIBC). Resolving any underlying iron sequestration will not only improve energy levels but will also increase the reliability of future HbA1c tests.
2. **Triglyceride Modulation**: The rise to 209 in a non-fasting state is significant. Reducing glycemic load (specifically fructose and refined grains) and increasing the intake of long-chain omega-3 fatty acids will help move this parameter toward the <150~mg/dL target.
3. **Hydration Awareness**: The BUN/Creatinine ratio of 21 indicates a need for structured hydration. Maintaining a blood volume that is not "concentrated" will ease the workload on the kidneys and provide more accurate measurement of waste products.
4. **Long-Term Cardiovascular Strategy**: With an LDL of 20, the patient is well-protected against the creation of new plaques. The focus should remain on the "quality" of the remaining particles by managing the triglycerides and HDL.

By integrating these disparate data points—from the physics of the red blood cell to the hormonal crosstalk of testosterone and insulin—the patient can navigate his health with precision. The overall trajectory is one of significant recovery and toward a state of metabolic organizational perfection.

Works cited

1. Dr. Brian Fertig: Metabolism & Medicine - What Is Metabolism?, http://fertigmetabolism.com/ 2. Author of Metabolism & Medicine - Dr. Brian Fertig MD, http://fertigmetabolism.com/about-author/ 3. Is hemoglobin A1c an accurate measure of glycemic control in all diabetic patients?, https://www.ccjm.org/content/ccjom/81/3/146.full.pdf 4. What is a C-Peptide Test? - WebMD, https://www.webmd.com/diabetes/what-is-c-peptide-test 5. Management of Cholesterol in Diabetes - A Review | USC Journal, https://www.uscjournal.com/articles/management-cholesterol-diabetes-review?language_content_entity=en 6. Metabolism and Medicine: Two Volume Set - 1st Edition - Brian Fertig - - Routledge, https://www.routledge.com/Metabolism-and-Medicine-Two-Volume-Set/Fertig/p/book/9781032126715 7. What doctors wish patients knew about high cholesterol | American Medical Association, https://www.ama-assn.org/public-health/chronic-diseases/what-doctors-wish-patients-knew-about-high-cholesterol 8. Impact of Mean Cell Hemoglobin on Hb A1c-Defined Glycemia Status - ResearchGate, https://www.researchgate.net/publication/308704452_Impact_of_Mean_Cell_Hemoglobin_on_Hb_A1c-Defined_Glycemia_Status 9. Impact of Anemia and Red Cell Indices on the Diagnosis of Pre-Diabetes and Diabetes in Indian Adult Population: Is there a Cut-off Guide for Clinicians? - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC6446692/ 10. Influence of Iron Deficiency Anemia on Hemoglobin A1C Levels in Diabetic Individuals with Controlled Plasma Glucose Levels - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC3933917/ 11. C-Peptide Test: MedlinePlus Medical Test, https://medlineplus.gov/lab-tests/c-peptide-test/ 12. C-Peptide (Blood) - Content - Health Encyclopedia - University of Rochester Medical Center, https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=167&contentid=c_peptide_blood 13. C-Peptide Test: What It Is, Purpose, Procedure & Results - Cleveland Clinic, https://my.clevelandclinic.org/health/diagnostics/24242-c-peptide-test 14. Insulin C-peptide test - UCSF Health, https://www.ucsfhealth.org/medical-tests/insulin-c-peptide-test 15. What does low C-peptide mean and what causes it? - SiPhox Health, https://siphoxhealth.com/articles/what-does-low-cpeptide-mean-and-what-causes-it 16. C-Peptide Test: Normal Range + Low & High Levels - SelfDecode Labs, https://labs.selfdecode.com/blog/c-peptide/ 17. Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC5937425/ 18. Does a patient with diabetes and borderline low Low-Density Lipoprotein (LDL) cholesterol need a statin (HMG-CoA reductase inhibitor)? - Dr.Oracle, https://www.droracle.ai/articles/30284/does-a-patient-with-diabetes-and-borderline-low-low-density 19. High Blood Triglycerides | NHLBI, NIH, https://www.nhlbi.nih.gov/health/high-blood-triglycerides 20.

Lab Report Analysis and Health Summary

https://www.medicalnewstoday.com/articles/321979 23. Triglycerides and Diabetes: What Are the Risks? - diaTribe.org, https://diatribe.org/diabetes-research/triglycerides-and-diabetes-what-are-risks 24. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC4929379/ 25. HDL (Good), LDL (Bad) Cholesterol and Triglycerides | American Heart Association, https://www.heart.org/en/health-topics/cholesterol/hdl-good-ldl-bad-cholesterol-and-triglycerides 26. Your Cholesterol Numbers: The Good, the Bad, the Triglycerides | News | Yale Medicine, https://www.yalemedicine.org/news/your-cholesterol-numbers-the-good-the-bad-the-triglycerides 27. The Bun Creatinine Ratio. The Biomarkers of Hydration and Renal Function. - MealPro, https://www.mealpro.net/blog/bun-creatinine-ratio-biomarkers-hydration-renal-function/ 28. BUN Creatinine Ratio - MDCalc, https://www.mdcalc.com/calc/10501/bun-creatinine-ratio 29. What does it mean when BUN creatinine ratio is high? | SiPhox Health, https://siphoxhealth.com/articles/what-does-it-mean-when-bun-creatinine-ratio-is-high 30. Blood Urea Nitrogen (BUN) Test - Kaiser Permanente, https://healthy.kaiserpermanente.org/health-wellness/health-encyclopedia/he.blood-urea-nitrogen-bun-test.aa36271 31. Anemia in Patients with Type 2 Diabetes Mellitus - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC4658398/ 32. Low MCHC symptoms and who's at risk - SingleCare, https://www.singlecare.com/blog/low-mchc-symptoms/ 33. Low MCHC in blood tests: Symptoms and causes - Medical News Today, https://www.medicalnewstoday.com/articles/319613 34. Understanding MCHC Blood Test Results - Health, https://www.health.com/mchc-blood-test-7092747 35. Normochromic Normocytic Anemia - StatPearls - NCBI Bookshelf - NIH, https://www.ncbi.nlm.nih.gov/books/NBK565880/ 36. Normocytic Anemia: What It Is, Causes & Symptoms - Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/22977-normocytic-anemia 37. Low and High MCHC in Blood Test: Causes, Symptoms, Treatment - MedicineNet, https://www.medicinenet.com/what_does_a_low_or_high_mchc_mean_in_a_blood_test/article.htm 38. Iron Deficiency Anemia - Hematology and Oncology - Merck Manual Professional Edition, https://www.merckmanuals.com/professional/hematology-and-oncology/anemias-caused-by-deficient-erythropoiesis/iron-deficiency-anemia 39. MCHC and MCV Blood Tests: What Do They Mean? - MyObesityTeam, https://www.myobesityteam.com/resources/mchc-and-mcv-blood-tests-what-do-they-mean 40. Volume 2: Metabolism & Medicine - How Metabolism Works, http://fertigmetabolism.com/volume-2/ 41. C-Reactive Protein: Clinical Relevance and Interpretation - StatPearls - NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK441843/ 42. C-Reactive Protein (CRP) Test: What It Is, Purpose & Results - Cleveland Clinic, https://my.clevelandclinic.org/health/diagnostics/23056-c-reactive-protein-crp-test 43. C-reactive protein - UCSF Health, https://www.ucsfhealth.org/medical-tests/c-reactive-protein 44. C-reactive protein test - Mayo Clinic, https://www.mayoclinic.org/tests-procedures/c-reactive-protein-test/about/pac-20385228 45. Creatine Kinase: MedlinePlus Medical Test, https://medlineplus.gov/lab-tests/creatine-kinase/ 46. Creatine Kinase (CK) Levels: Normal Ranges and What It Means - Jinfiniti, https://www.jinfiniti.com/creatine-kinase-test-levels/ 47. Creatine Kinase (CK) Levels Test: What It Is and Results - Verywell Health, https://www.verywellhealth.com/creatine-kinase-5324660 48. Normal Testosterone Levels by Age - Baptist Health, https://www.baptisthealth.com/blog/mens-health/normal-testosterone-levels-by-age 49. What Are Normal Testosterone Levels by Age? | Gameday Men's Health, https://gamedaymenshealth.com/blog/what-are-normal-testosterone-levels-by-age/ 50. SHBG and total testosterone levels in men with adult onset ... - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC7526370/ 51. Triglycerides: Why do they matter? - Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/triglycerides/art-20048186 52. The Truth About Triglycerides - University of Rochester Medical Center, https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=56&contentid=2967